Christi Shaw

SVP and Pres., Lilly Bio-Meds, Eli Lilly and Company.

Companies

Kyverna Therapeutics, Inc.Chair Jan 14, 2026 to now¹
Kyverna Therapeutics, Inc.Board member Sep 18, 2024 to now²
Beam TherapeuticsBoard member Dec 14, 2023 to now³
AvantorBoard member May 16, 2019 to May 15, 2023⁴
Eli Lilly and CompanySVP and Pres., Lilly Bio-Meds Apr 10, 2017 to May 16, 2019⁵

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

As of each latest filing. The line shows shares held over time.

May 27, 2026Shares withheld for tax 4,194 shares at $8.59 of Kyverna Therapeutics, Inc.⁸
Jan 12, 2026Granted 24,301 shares of Kyverna Therapeutics, Inc.⁹
Jan 12, 2026Granted 30,000 shares of Kyverna Therapeutics, Inc.⁹
May 29, 2025Granted 16,634 shares of Kyverna Therapeutics, Inc.¹⁰
May 11, 2023Granted 9,808 shares of Avantor⁷
May 12, 2022Granted 6,693 shares of Avantor¹¹
Apr 1, 2022Granted 1,215 shares of Avantor¹²
May 3, 2019Sold 500 shares at $117.99 of Eli Lilly and Company¹³
May 3, 2019Sold 7,077 shares at $117.08 of Eli Lilly and Company⁶
May 3, 2019Sold 7,077 shares at $117.08 of Eli Lilly and Company¹³
May 1, 2019Shares withheld for tax 6,173 shares at $117.04 of Eli Lilly and Company¹⁴
May 1, 2019Exercised options 13,750 shares of Eli Lilly and Company¹⁴
May 29, 2018Sold 8,426 shares at $82.10 of Eli Lilly and Company¹⁵
May 29, 2018Sold 8,426 shares at $82.10 of Eli Lilly and Company¹⁶
May 1, 2018Shares withheld for tax 5,324 shares at $81.07 of Eli Lilly and Company¹⁷
May 1, 2018Exercised options 13,750 shares of Eli Lilly and Company¹⁷

Date	Stock	Trade	Value	Return since	Vs S&P since	Vs S&P, 1 year
May 3, 2019	LLY	Sale	$1.7M	+970.6%	−808.1%	−34.7%

Returns are price-only (no dividends), measured from the trade date.

The numbers on this page point here. Each one links to the record it came from.